Recent evidence suggests an association of Arg388 single nucleotide polymorphism (SNP) in the fibroblast growth factor receptor 4 (FGFR4) gene and outcome in node-positive (N+) breast cancer. For the first time, we address the clinical relevance of this SNP, FGFR4 expression, and HER2 regarding outcome and adjuvant therapy response in a representative breast cancer cohort (n=372). In N+ but not N0 patients, FGFR4Arg388 is significantly associated with poor prognosis. This seems to be attributable to poorer response to adjuvant systemic therapy as reflected in significantly shorter survival and a significant interaction in a multivariate proportional hazards model with Arg388 carriers having only about half as much benefit from adjuvant systemic therapy as wild-type carriers. FGFR4Arg388 seems to be a marker for breast cancer progression in patients with adjuvant systemic therapy, and thus may indicate therapy resistance.
«
Recent evidence suggests an association of Arg388 single nucleotide polymorphism (SNP) in the fibroblast growth factor receptor 4 (FGFR4) gene and outcome in node-positive (N+) breast cancer. For the first time, we address the clinical relevance of this SNP, FGFR4 expression, and HER2 regarding outcome and adjuvant therapy response in a representative breast cancer cohort (n=372). In N+ but not N0 patients, FGFR4Arg388 is significantly associated with poor prognosis. This seems to be attributabl...
»